HIPK2 and Alzheimer disease: Since one of the features that distinguishes AD from non-AD fibroblasts is a defective non-amyloidogenic APP processing, likely favouring an aberrant Aβ peptides production [26], these data suggest that this abnormality may be, at least in part, responsible for altered HIPK2 binding to promoters.